Brain opioid innervation is involved in many pathophysiological processes related to drug addiction. The main idea of the present review is that μ-/δ-opioid innervation is an intrinsic component of the motor/approach behavior network, which is activated synergetically with dopaminergic mesocorticolimbic network. Contribution of opioid innervation to the motor/approach behavior processing includes generation of positive emotions and inhibition of pain and stress reactions in order that the individual would be able to reach the vital goal. We cite the neuroanatomical data which showed that motor subcortical nuclei contain the most abundant opioid innervation and its activation is an obligatory component of positive emotions. In the majority of life situations, motor/approach behavior network concomitantly activates pain/stress control opioid network. Intensive cognitive activity induces activation of opioid innervation as well, and both enhancing and impairing effects of opioid agonists on cognitive functioning were demonstrated. Overall, the functioning of endogenous opioid networks may be summarized as following: NO physical/cognitive activity？=？NO positive emotions plus NO pain/stress control. We suppose that contemporary findings concerning neuropsychological functions of endogenous opioid system explain many controversial issues in neuropsychiatric conditions predisposing to drug addiction and neurological mechanisms of opioid addiction. 1. Introduction Brain opioid innervation is intrinsically involved in many pathophysiological processes related to drug addiction. Multiple experimental studies showed that endogenous opioid system is not only the target of opioid addictive drugs but is also activated during alcohol and psychostimulants consumption [1, 2]. Moreover, genetic characteristics of endogenous brain opioid system are an important factor predisposing to drug abuse and addiction. In addicted populations, the frequency of G allele of -opioid receptor is almost twice as high as in healthy populations [3, 4], and the efficacy of detoxification of alcoholic patients with G allele was shown to be lower in comparison with A/A genotype [5]. Ray and colleagues [6] observed higher levels of vigor and lower levels negative mood in alcoholics with Asp40 allele of the -opioid receptor gene in comparison with alcoholics who were homozygotes for the Asn40 variants. Association between cocaine addiction and polymorphism of -opioid receptor was shown in humans as well [7]. Insufficient activity of endogenous brain opioid systems appears to predispose to drug
References
[1]
J. Le Merrer, J. A. J. Becker, K. Befort, and B. L. Kieffer, “Reward processing by the opioid system in the brain,” Physiological Reviews, vol. 89, no. 4, pp. 1379–1412, 2009.
[2]
J. H. Yoo, I. Kitchen, and A. Bailey, “The endogenous opioid system in cocaine addiction: what lessons have opioid peptide and receptorknockout mice taught us?” British Journal of Pharmacology, vol. 166, no. 7, pp. 1993–2014, 2012.
[3]
D. Kumar, J. Chakraborty, and S. Das, “Epistatic effects between variants of kappa-opioid receptor gene and A118G of mu-opioid receptor gene increase susceptibility to addiction in Indian population,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 36, no. 2, pp. 225–230, 2012.
[4]
D. Nagaya, S. Ramanathan, M. Ravichandran, and V. Navaratnam, “A118G mu opioid receptor polymorphism among drug addicts in Malaysia,” Journal of Integrative Neuroscience, vol. 11, no. 1, pp. 117–122, 2012.
[5]
V. Marini, C. Fucile, M. L. Zuccoli et al., “Involvement of the mu-opioid receptor gene polymorphism A118G in the efficacy of detoxification of alcohol dependent patients,” Addictive Behaviors, vol. 38, no. 3, pp. 1669–1671, 2013.
[6]
L. A. Ray, R. Miranda Jr., J. W. Tidey et al., “Polymorphisms of the μ-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment,” Journal of Abnormal Psychology, vol. 119, no. 1, pp. 115–125, 2010.
[7]
R. C. Crist, L. M. Ambrose-Lanci, M. Vaswani et al., “Case-control association analysis of polymorphisms in the delta-opioid receptor, OPRD1, with cocaine and opioid addicted populations,” Drug and Alcohol Dependence, vol. 127, no. 1–3, pp. 122–8, 2013.
[8]
J. E. Learn, E. Chernet, W. J. McBride, L. Lumeng, and T.-K. Li, “Quantitative autoradiography of Mu-opioid receptors in the CNS of high-alcohol-drinking (HAD) and low-alcohol-drinking (LAD) rats,” Alcoholism, vol. 25, no. 4, pp. 524–530, 2001.
[9]
S. Martín, J. Manzanares, J. Corchero et al., “Differential basal proenkephalin gene expression in dorsal striatum and nucleus accumbens, and vulnerability to morphine self-administration in Fischer 344 and Lewis rats,” Brain Research, vol. 821, no. 2, pp. 350–355, 1999.
[10]
D. L. Mangold, M. Peyrot, P. Giggey, and G. S. Wand, “Endogenous opioid activity is associated with obsessive-compulsive symptomology in individuals with a family history of alcoholism,” Neuropsychopharmacology, vol. 22, no. 6, pp. 595–607, 2000.
[11]
A. Torres-Reveron, T. J. Williams, J. D. Chapleau et al., “Ovarian steroids alter mu opioid receptor trafficking in hippocampal parvalbumin GABAergic interneurons,” Experimental Neurology, vol. 219, no. 1, pp. 319–327, 2009.
[12]
D. R. Loyd, X. Wang, and A. Z. Murphy, “Sex differences in μ-opioid receptor expression in the rat midbrain periaqueductal gray are essential for eliciting sex differences in morphine analgesia,” Journal of Neuroscience, vol. 28, no. 52, pp. 14007–14017, 2008.
[13]
T. J. Williams, A. Torres-Reveron, J. D. Chapleau, and T. A. Milner, “Hormonal regulation of delta opioid receptor immunoreactivity in interneurons and pyramidal cells in the rat hippocampus,” Neurobiology of Learning and Memory, vol. 95, no. 2, pp. 206–220, 2011.
[14]
Z. Vucetic, J. Kimmel, K. Totoki, E. Hollenbeck, and T. M. Reyes, “Maternal high-fat diet alters methylation and gene expression of dopamine and opioid-related genes,” Endocrinology, vol. 151, no. 10, pp. 4756–4764, 2010.
[15]
G. Kiosterakis, A. Stamatakis, A. Diamantopoulou, M. Fameli, and F. Stylianopoulou, “Long-term effects of neonatal handling on Mu-opioid receptor levels in the brain of the offspring,” Developmental Psychobiology, vol. 51, no. 5, pp. 439–449, 2009.
[16]
A. B. Gekht, A. G. Polunina, E. A. Bryun, and E. I. Gusev, “Neurological disturbances in heroin addicts in acute withdrawal and early postabstinence periods,” Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova, vol. 103, no. 2, pp. 9–15, 2003.
[17]
A. A. Kozlov, I. V. Dorovskih, N. A. Doljanskaia, T. S. Buzina, and A. G. Polunina, “Psychopathological disorders in heroin addicts and administration of risperidone during rehabilitation,” Heroin Addiction and Related Clinical Problems, vol. 7, no. 4, pp. 31–41, 2005.
[18]
I. N. Piatnizkaya, Drug Addiction, Medicina, Moscow, Russia, 1994.
[19]
S. Kaye, S. Darke, and R. Finlay-Jones, “The onset of heroin use and criminal behaviour: does order make a difference?” Drug and Alcohol Dependence, vol. 53, no. 1, pp. 79–86, 1998.
[20]
K. P. Conway, R. J. Kane, S. A. Ball, J. C. Poling, and B. J. Rounsaville, “Personality, substance of choice, and polysubstance involvement among substance dependent patients,” Drug and Alcohol Dependence, vol. 71, no. 1, pp. 65–75, 2003.
[21]
V. V. Chirko, “The course and outcome of drug addiction according to long-term follow-up study,” Zhurnal Nevropatolgii i Psikhiatrii im. S S Korsakova, vol. 98, no. 6, pp. 19–22, 1998.
[22]
S. Darke, A. Williamson, J. Ross, and M. Teesson, “Attempted suicide among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS),” Drug and Alcohol Dependence, vol. 78, no. 2, pp. 177–186, 2005.
[23]
D. A. Eisinger, H. Ammer, and R. Schulz, “Chronic morphine treatment inhibits opioid receptor desensitization and internalization,” Journal of Neuroscience, vol. 22, no. 23, pp. 10192–10200, 2002.
[24]
C. E. Groer, C. L. Schmid, A. M. Jaeger, and L. M. Bohn, “Agonist-directed interactions with specific β-arrestins determine μ-opioid receptor trafficking, ubiquitination, and dephosphorylation,” Journal of Biological Chemistry, vol. 286, no. 36, pp. 31731–31741, 2011.
[25]
T. C. Napier and I. Mitrovic, “Opioid modulation of ventral pallidal inputs,” Annals of the New York Academy of Sciences, vol. 877, pp. 176–201, 1999.
[26]
J. M. Van Ree, M. A. F. M. Gerrits, and L. J. M. J. Vanderschuren, “Opioids, reward and addiction: an encounter of biology, psychology, and medicine,” Pharmacological Reviews, vol. 51, no. 2, pp. 341–396, 1999.
[27]
A. Janecka, J. Fichna, and T. Janecki, “Opioid receptors and their ligands,” Current Topics in Medicinal Chemistry, vol. 4, no. 1, pp. 1–17, 2004.
[28]
A. D. Corbett, G. Henderson, A. T. McKnight, and S. J. Paterson, “75 Years of opioid research: the exciting but vain quest for the Holy Grail,” British Journal of Pharmacology, vol. 147, no. 1, pp. S153–S162, 2006.
[29]
A. Koneru, S. Satyanarayana, and S. Rizwan, “Endogenous opioids: their physiological role and receptors,” Global Journal of Pharmacology, vol. 3, no. 3, pp. 149–153, 2009.
[30]
J. B. Penney, “Neurochemical Neuroanatomy,” in Neuropsychiatry, B. S. Fogel, R. B. Schiffer, and S. M. Rao, Eds., pp. 635–678, Williams and Wilkins, 1996.
[31]
J. Fichna, A. Janecka, J. Costentin, and J.-C. Do Rego, “The endomorphin system and its evolving neurophysiological role,” Pharmacological Reviews, vol. 59, no. 1, pp. 88–123, 2007.
[32]
P. Fine and R. K. Portenoy, Opioid Analgesia, McGraw Hill, New York, NY, USA, 2004.
[33]
C. Ikonomidou-Turski, E. A. Cavalheiro, and W. A. Turski, “Convulsant action of morphine, [D-Ala2, D-LEU5]-enkephalin and naloxone in the rat amygdala: electroencephalographic, morphological and behavioural sequelae,” Neuroscience, vol. 20, no. 2, pp. 671–686, 1987.
[34]
A. Fernandez-Guardiola, F. Pellicer, L. Rocha, and R. Gutierrez, “Naloxone facilitates sensory precipitation of focal and generalized seizures: evoked potentials and power spectral analysis in the cat,” Experimental Neurology, vol. 101, no. 2, pp. 159–175, 1988.
[35]
H. Wilkie, A. Osei-Lah, B. Chioza et al., “Association of μ-opioid receptor subunit gene and idiopathic generalized epilepsy,” Neurology, vol. 59, no. 5, pp. 724–728, 2002.
[36]
A. T. Knoll and W. A. Carlezon Jr., “Dynorphin, stress, and depression,” Brain Research, vol. 1314, pp. 56–73, 2010.
[37]
M. D. Avia, “Personality and positive emotions,” European Journal of Personality, vol. 11, no. 1, pp. 33–56, 1997.
[38]
J. J. Gross and R. A. Thompson, “Emotion regulation: conceptual foundations,” in Handbook of Emotion Regulation, J. J. Gross, Ed., Guilford Press, New York, NY, USA, 2007.
[39]
R. A. Wise, “Brain reward circuitry: insights from unsensed incentives,” Neuron, vol. 36, no. 2, pp. 229–240, 2002.
[40]
K. S. Smith and K. C. Berridge, “Opioid limbic circuit for reward: interaction between hedonic hotspots of nucleus accumbens and ventral pallidum,” Journal of Neuroscience, vol. 27, no. 7, pp. 1594–1605, 2007.
[41]
B. Bontempi and F. R. Sharp, “Systemic morphine-induced Fos protein in the rat striatum and nucleus accumbens is regulated by μ opioid receptors in the substantia nigra and ventral tegmental area,” Journal of Neuroscience, vol. 17, no. 21, pp. 8596–8612, 1997.
[42]
S. N. Haber and B. Knutson, “The reward circuit: linking primate anatomy and human imaging,” Neuropsychopharmacology, vol. 35, no. 1, pp. 4–26, 2010.
[43]
S. R. Sesack and A. A. Grace, “Cortico-basal ganglia reward network: microcircuitry,” Neuropsychopharmacology, vol. 35, no. 1, pp. 27–47, 2010.
[44]
A. Mansour, H. Khachaturian, M. E. Lewis, H. Akil, and S. J. Watson, “Anatomy of CNS opioid receptors,” Trends in Neurosciences, vol. 11, no. 7, pp. 308–314, 1988.
[45]
U. Baumg？rtner, H.-G. Buchholz, A. Bellosevich et al., “High opiate receptor binding potential in the human lateral pain system,” NeuroImage, vol. 30, no. 3, pp. 692–699, 2006.
[46]
K. S. Smith, A. J. Tindell, J. W. Aldridge, and K. C. Berridge, “Ventral pallidum roles in reward and motivation,” Behavioural Brain Research, vol. 196, no. 2, pp. 155–167, 2009.
[47]
P. I. Johnson and J. R. Stellar, “Comparison of delta opiate receptor agonist induced reward and motor effects between the ventral pallidum and dorsal striatum,” Neuropharmacology, vol. 33, no. 10, pp. 1171–1182, 1994.
[48]
M. L. Kringelbach and K. C. Berridge, “Towards a functional neuroanatomy of pleasure and happiness,” Trends in Cognitive Sciences, vol. 13, no. 11, pp. 479–487, 2009.
[49]
A. G. Di Feliceantonio, O. S. Mabrouk, R. T. Kennedy, and K. C. Berridge, “Enkephalin surges in dorsal neostriatum as a signal to eat,” Current of Biology, vol. 22, no. 20, pp. 1918–1924, 2012.
[50]
C. K. Nielsen, J. A. Simms, R. Li et al., “δ-opioid receptor function in the dorsal striatum plays a role in high levels of ethanol consumption in rats,” Journal of Neuroscience, vol. 32, no. 13, pp. 4540–4552, 2012.
[51]
A. V. Zuikov, T. P. Semenova, I. I. Kozlovskiy, N. M. Zakharova, L. A. Andreeva, and M. M. Kozlovskaya, “Adaptive behavior and the state of functional activity of the endogenous opioid system,” Psychopharmacology and Biological Narcology, vol. 9, no. 1-2, pp. 2510–2516, 2009.
[52]
M. Jabourian, L. Venance, S. Bourgoin et al., “Functional mu opioid receptors are expressed in cholinergic interneurons of the rat dorsal striatum: territorial specificity and diurnal variation,” European Journal of Neuroscience, vol. 21, no. 12, pp. 3301–3309, 2005.
[53]
G. Ponterio, A. Tassone, G. Sciamanna et al., “Powerful inhibitory action of mu opioid receptors (MOR) on cholinergic interneuron excitability in the dorsalstriatum,” Neuropharmacology, vol. 75C, pp. 78–85, 2013.
[54]
L. J. Vogt, L. J. Sim-Selley, S. R. Childers, R. G. Wiley, and B. A. Vogt, “Colocalization of μ-opioid receptors and activated G-proteins in rat cingulate cortex,” Journal of Pharmacology and Experimental Therapeutics, vol. 299, no. 3, pp. 840–848, 2001.
[55]
J. M. Evans, V. Bey, A. R. Burkey, and K. G. Commons, “Organization of endogenous opioids in the rostral agranular insular cortex of the rat,” Journal of Comparative Neurology, vol. 500, no. 3, pp. 530–541, 2007.
[56]
L. Becerra, K. Harter, R. Gilberto Gonzalez, and D. Borsook, “Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers,” Anesthesia and Analgesia, vol. 103, no. 1, pp. 208–216, 2006.
[57]
M. Lepp？, A. Korvenoja, S. Carlson et al., “Acute opioid effects on human brain as revealed by functional magnetic resonance imaging,” NeuroImage, vol. 31, no. 2, pp. 661–669, 2006.
[58]
B. J. MacIntosh, K. T. S. Pattinson, D. Gallichan et al., “Measuring the effects of remifentanil on cerebral blood flow and arterial arrival time using 3D GRASE MRI with pulsed arterial spin labelling,” Journal of Cerebral Blood Flow and Metabolism, vol. 28, no. 8, pp. 1514–1522, 2008.
[59]
N. Khalili-Mahani, M. J. P. van Osch, E. Baerends et al., “Pseudocontinuous arterial spin labeling reveals dissociable effects of morphine and alcohol on regional cerebral blood flow,” Journal of Cerebral Blood Flow and Metabolism, vol. 31, no. 5, pp. 1321–1333, 2011.
[60]
T. E. Schlaepfer, E. C. Strain, B. D. Greenberg et al., “Site of opioid action in the human brain: Mu and kappa agonists' subjective and cerebral blood flow effects,” The American Journal of Psychiatry, vol. 155, no. 4, pp. 470–473, 1998.
[61]
P. Petrovic, B. Pleger, B. Seymour et al., “Blocking central opiate function modulates hedonic impact and anterior cingulate response to rewards and losses,” Journal of Neuroscience, vol. 28, no. 42, pp. 10509–10516, 2008.
[62]
R. D. Rogers, A. M. Owen, H. C. Middleton et al., “Choosing between small, likely rewards and large, unlikely rewards activates inferior and orbital prefrontal cortex,” Journal of Neuroscience, vol. 19, no. 20, pp. 9029–9038, 1999.
[63]
S. M. Tom, C. R. Fox, C. Trepel, and R. A. Poldrack, “The neural basis of loss aversion in decision-making under risk,” Science, vol. 315, no. 5811, pp. 515–518, 2007.
[64]
F. D. Zeeb, T. W. Robbins, and C. A. Winstanley, “Serotonergic and dopaminergic modulation of gambling behavior as assessed using a novel rat gambling task,” Neuropsychopharmacology, vol. 34, no. 10, pp. 2329–2343, 2009.
[65]
S. V. Mahler and K. C. Berridge, “Which cue to “Want?“ central amygdala opioid activation enhances and focuses incentive salience on a prepotent reward cue,” Journal of Neuroscience, vol. 29, no. 20, pp. 6500–6513, 2009.
[66]
T. E. Robinson and K. C. Berridge, “The neural basis of drug craving: an incentive-sensitization theory of addiction,” Brain Research Reviews, vol. 18, no. 3, pp. 247–291, 1993.
[67]
T. E. Robinson and K. C. Berridge, “Addiction,” Annual Review of Psychology, vol. 54, pp. 25–53, 2003.
[68]
K. C. Berridge and J. W. Aldridge, “Decision utility, the brain, and pursuit of hedonic goals,” Social Cognition, vol. 26, no. 5, pp. 621–646, 2008.
[69]
V. Bassareo, M. A. De Luca, and G. Di Chiara, “Differential expression of motivational stimulus properties by dopamine in nucleus accumbens shell versus core and prefrontal cortex,” Journal of Neuroscience, vol. 22, no. 11, pp. 4709–4719, 2002.
[70]
A. Faure, S. M. Reynolds, J. M. Richard, and K. C. Berridge, “Mesolimbic dopamine in desire and dread: enabling motivation to be generated by localized glutamate disruptions in nucleus accumbens,” Journal of Neuroscience, vol. 28, no. 28, pp. 7184–7192, 2008.
[71]
M. R. Delgado, L. E. Nystrom, C. Fissell, D. C. Noll, and J. A. Fiez, “Tracking the hemodynamic responses to reward and punishment in the striatum,” Journal of Neurophysiology, vol. 84, no. 6, pp. 3072–3077, 2000.
[72]
J. C. Cooper and B. Knutson, “Valence and salience contribute to nucleus accumbens activation,” NeuroImage, vol. 39, no. 1, pp. 538–547, 2008.
[73]
R. J. Davidson, D. C. Jackson, and N. H. Kalin, “Emotion, plasticity, context, and regulation: perspectives from affective neuroscience,” Psychological Bulletin, vol. 126, no. 6, pp. 890–909, 2000.
[74]
K. Morinaga, J. Akiyoshi, H. Matsushita et al., “Anticipatory anxiety-induced changes in human lateral prefrontal cortex activity,” Biological Psychology, vol. 74, no. 1, pp. 34–38, 2007.
[75]
D. H. Zald, I. Boileau, W. El-Dearedy et al., “Dopamine transmission in the human striatum during monetary reward tasks,” Journal of Neuroscience, vol. 24, no. 17, pp. 4105–4112, 2004.
[76]
N. Hagelberg, S. Aalto, J. Kajander et al., “Alfentanil increases cortical dopamine D2/D3 receptor binding in healthy subjects,” Pain, vol. 109, no. 1-2, pp. 86–93, 2004.
[77]
N. Hagelberg, J. K. Kajander, K. N？gren, S. Hinkka, J. Hietala, and H. Scheinin, “μ-receptor agonism with alfentanil increases striatal dopamine D2 receptor binding in man,” Synapse, vol. 45, no. 1, pp. 25–30, 2002.
[78]
W. Chen and J. C. G. Marvizón, “Acute inflammation induces segmental, bilateral, supraspinally mediated opioid release in the rat spinal cord, as measured by μ-opioid receptor internalization,” Neuroscience, vol. 161, no. 1, pp. 157–172, 2009.
[79]
R. W. Gear, K. O. Aley, and J. D. Levine, “Pain-induced analgesia mediated by mesolimbic reward circuits,” Journal of Neuroscience, vol. 19, no. 16, pp. 7175–7181, 1999.
[80]
J.-K. Zubieta and C. S. Stohler, “Neurobiological mechanisms of placebo responses,” Annals of the New York Academy of Sciences, vol. 1156, pp. 198–210, 2009.
[81]
J. Maarrawi, R. Peyron, P. Mertens et al., “Differential brain opioid receptor availability in central and peripheral neuropathic pain,” Pain, vol. 127, no. 1-2, pp. 183–194, 2007.
[82]
C. Mueller, A. Klega, H.-G. Buchholz et al., “Basal opioid receptor binding is associated with differences in sensory perception in healthy human subjects: a [18F]diprenorphine PET study,” NeuroImage, vol. 49, no. 1, pp. 731–737, 2010.
[83]
M. S. R. de Oliveira, M. J. da Silva Fernandes, F. A. Scorza et al., “Acute and chronic exercise modulates the expression of MOR opioid receptors in the hippocampal formation of rats,” Brain Research Bulletin, vol. 83, no. 5, pp. 278–283, 2010.
[84]
C. Sprenger, F. Eippert, J. Finsterbusch, U. Bingel, M. Rose, and C. Büchel, “Attention modulates spinal cord responses to pain,” Current Biology, vol. 22, no. 11, pp. 1019–1022, 2012.
[85]
A. Z. Murphy, S. K. Suckow, M. Johns, and R. J. Traub, “Sex differences in the activation of the spinoparabrachial circuit by visceral pain,” Physiology and Behavior, vol. 97, no. 2, pp. 205–212, 2009.
[86]
M. S. Cepeda and D. B. Carr, “Women experience more pain and require more morphine than men to achieve a similar degree of analgesia,” Anesthesia and Analgesia, vol. 97, no. 5, pp. 1464–1468, 2003.
[87]
E.-C. Tan, E. C. P. Lim, Y.-Y. Teo, Y. Lim, H.-Y. Law, and A. T. Sia, “Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain,” Molecular Pain, vol. 5, article 32, 2009.
[88]
S. Bruehl, O. Y. Chung, and J. W. Burns, “The mu opioid receptor A118G gene polymorphism moderates effects of trait anger-out on acute pain sensitivity,” Pain, vol. 139, no. 2, pp. 406–415, 2008.
[89]
S. Bruehl, O. Y. Chung, J. W. Burns, and L. Diedrich, “Trait anger expressiveness and pain-induced beta-endorphin release: support for the opioid dysfunction hypothesis,” Pain, vol. 130, no. 3, pp. 208–215, 2007.
[90]
N. Silver, R. P. Allen, J. Senerth, and C. J. Earley, “A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome,” Sleep Medicine, vol. 12, no. 5, pp. 440–444, 2011.
[91]
A. S. Walters, W. G. Ondo, W. Zhu, and W. Le, “Does the endogenous opiate system play a role in the restless legs syndrome?: a pilot post-mortem study,” Journal of the Neurological Sciences, vol. 279, no. 1-2, pp. 62–65, 2009.
[92]
A. Klega, T. Eberle, H.-G. Buchholz et al., “Central opioidergic neurotransmission in complex regional pain syndrome,” Neurology, vol. 75, no. 2, pp. 129–136, 2010.
[93]
A. K. P. Jones, V. J. Cunningham, S. Ha-Kawa et al., “Changes in central opioid receptor binding in relation to inflammation and pain in patients with rheumatoid arthritis,” British Journal of Rheumatology, vol. 33, no. 10, pp. 909–916, 1994.
[94]
P. E. Lutz and B. L. Kieffer, “Opioid receptors: distinct roles in mood disorders,” Trends in Neurosciences, vol. 36, no. 3, pp. 195–206, 2013.
[95]
A. Bandura, D. Cioffi, C. B. Taylor, and M. E. Brouillard, “Perceived self-efficacy in coping with cognitive stressors and opioid activation,” Journal of Personality and Social Psychology, vol. 55, no. 3, pp. 479–488, 1988.
[96]
D. Parikh, A. Hamid, T. C. Friedman et al., “Stress-induced analgesia and endogenous opioid peptides: the importance of stress duration,” European Journal of Pharmacology, vol. 650, no. 2-3, pp. 563–567, 2011.
[97]
B. Bandelow, C. Schmahl, P. Falkai, and D. Wedekind, “Borderline personality disorder: a dysregulation of the endogenous opioid system?” Psychological Review, vol. 117, no. 2, pp. 623–636, 2010.
[98]
A. R. Prossin, T. M. Love, R. A. Koeppe, J.-K. Zubieta, and K. R. Silk, “Dysregulation of regional endogenous opioid function in borderline personality disorder,” The American Journal of Psychiatry, vol. 167, no. 8, pp. 925–933, 2010.
[99]
B. Stanley, L. Sher, S. Wilson, R. Ekman, Y.-Y. Huang, and J. J. Mann, “Non-suicidal self-injurious behavior, endogenous opioids and monoamine neurotransmitters,” Journal of Affective Disorders, vol. 124, no. 1-2, pp. 134–140, 2010.
[100]
S. E. Kennedy, R. A. Koeppe, E. A. Young, and J.-K. Zubieta, “Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women,” Archives of General Psychiatry, vol. 63, no. 11, pp. 1199–1208, 2006.
[101]
H. A. Garriock, M. Tanowitz, J. B. Kraft et al., “Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder,” The American Journal of Psychiatry, vol. 167, no. 5, pp. 565–573, 2010.
[102]
J.-K. Zubieta, T. A. Ketter, J. A. Bueller et al., “Regulation of human affective responses by anterior cingulate and limbic μ-opioid neurotransmission,” Archives of General Psychiatry, vol. 60, no. 11, pp. 1145–1153, 2003.
[103]
I. Liberzon, J. K. Zubieta, L. M. Fig, K. L. Phan, R. A. Koeppe, and S. F. Taylor, “μ-Opioid receptors and limbic responses to aversive emotional stimuli,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 10, pp. 7084–7089, 2002.
[104]
E. Bertoletti, A. Zanoni, R. Giorda, and M. Battaglia, “Influence of the OPRM1 gene polymorphism upon children's degree of withdrawal and brain activation in response to facial expressions,” Developmental Cognitive Neuroscience, vol. 2, no. 1, pp. 103–109, 2012.
[105]
J. F. Randall-Thompson, K. A. Pescatore, and E. M. Unterwald, “A role for delta opioid receptors in the central nucleus of the amygdala in anxiety-like behaviors,” Psychopharmacology, vol. 212, no. 4, pp. 585–595, 2010.
[106]
A. Saitoh and M. Yamada, “Antidepressant-like effects of d opioid receptor agonists in animal models,” Current Neuropharmacology, vol. 10, no. 3, pp. 231–238, 2012.
[107]
B. C. H. Chieng, M. J. Christie, and P. B. Osborne, “Characterization of neurons in the rat central nucleus of the amygdala: cellular physiology, morphology, and opioid sensitivity,” Journal of Comparative Neurology, vol. 497, no. 6, pp. 910–927, 2006.
[108]
M. A. Beckerman and M. J. Glass, “The NMDA-NR1 receptor subunit and the mu-opioid receptor are expressed in somatodendritic compartments of central nucleus of the amygdala neurons projecting to the bed nucleus of the stria terminalis,” Experimental Neurology, vol. 234, no. 1, pp. 112–126, 2012.
[109]
M. A. Beckerman and M. J. Glass, “Ultrastructural relationship between the AMPA-GluR2 receptor subunit and the mu-opioid receptor in the mouse central nucleus of the amygdala,” Experimental Neurology, vol. 227, no. 1, pp. 149–158, 2011.
[110]
J.-C. Kung, T.-C. Chen, B.-C. Shyu, S. Hsiao, and A. C. W. W. Huang, “Anxiety- and depressive-like responses and c-fos activity in preproenkephalin klockout mice: oversensitivity hypothesis of enkephalin deficit-induced posttraumatic stress disorder,” Journal of Biomedical Science, vol. 17, article 29, 2010.
[111]
M. A. Whittington, R. D. Traub, H. J. Faulkner, J. G. R. Jefferys, and K. Chettiar, “Morphine disrupts long-range synchrony of gamma oscillations in hippocampal slices,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 10, pp. 5807–5811, 1998.
[112]
J. S. Rodefer and T. N. Nguyen, “Naltrexone reverses age-induced cognitive deficits in rats,” Neurobiology of Aging, vol. 29, no. 2, pp. 309–313, 2008.
[113]
A. Mailis-Gagnon, S. F. Lakha, A. Furlan, K. Nicholson, B. Yegneswaran, and R. Sabatowski, “Systematic review of the quality and generalizability of studies on the effects of opioids on driving and cognitive/psychomotor performance,” Clinical Journal of Pain, vol. 28, no. 6, pp. 542–555, 2012.
[114]
M. L. F. Chaves, J. W. J. Bizzi, A. L. Palmini, and I. Izquierdo, “Naltrexone blocks the enhancing effect of novel experiences on performance in memory tests in humans,” Neuropsychologia, vol. 26, no. 3, pp. 491–494, 1988.
[115]
L. L. Hernández, K. L. Watson, B. M. Fowler, K. D. Bair, and A. K. Singha, “Opioid modulation of attention-related responses: peripheral-to-central progression and development of mu influence as learning occurs,” Psychopharmacology, vol. 132, no. 1, pp. 50–60, 1997.
[116]
M. R. Holahan, J. Nichol, and D. Madularu, “Spatial information processing consequences of DAMGO injections into the dorsal striatum,” Neurobiology of Learning and Memory, vol. 90, no. 2, pp. 434–442, 2008.
[117]
L. Pessoa and J. B. Engelmann, “Embedding reward signals into perception and cognition,” Frontiers in Neuroscience, vol. 4, article 17, 2010.
[118]
G. V. Morozov and N. N. Bogolepov, Morphinism, Medizina, Moscow, Russia, 1984.
[119]
T. E. Robinson, G. Gorny, V. R. Savage, and B. Kolb, “Widespread but regionally specific effects of experimenter- versus self-administered morphine on dendritic spines in the nucleus accumbens, hippocampus, and neocortex of adult rats,” Synapse, vol. 46, no. 4, pp. 271–279, 2002.
[120]
I. Ballesteros-Yá？ez, E. Ambrosio, R. Benavides-Piccione et al., “The effects of morphine self-administration on cortical pyramidal cell structure in addiction-prone lewis rats,” Cerebral Cortex, vol. 17, no. 1, pp. 238–249, 2007.
[121]
A. J. Eisch, M. Barrot, C. A. Schad, D. W. Self, and E. J. Nestler, “Opiates inhibit neurogenesis in the adult rat hippocampus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 13, pp. 7579–7584, 2000.
[122]
B. J. Everitt, A. Dickinson, and T. W. Robbins, “The neuropsychological basis of addictive behaviour,” Brain Research Reviews, vol. 36, no. 2-3, pp. 129–138, 2001.
[123]
A. E. Kelley, “Memory and addiction: shared neural circuitry and molecular mechanisms,” Neuron, vol. 44, no. 1, pp. 161–179, 2004.
[124]
A. G. Polunina and E. A. Bryun, “Orbitofrontal cortex in the genesis of in drug addiction,” Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova, vol. 111, no. 1, pp. 102–109, 2011.
[125]
D. Koyyalagunta, E. Bruera, C. Aigner, H. Nusrat, L. Driver, and D. Novy, “Risk stratification of opioid misuse among patients with cancer pain using the SOAPP-SF,” Pain Medicine, vol. 14, no. 5, pp. 667–675, 2013.
[126]
I. S. Yim, L. M. Glynn, C. D. Schetter, C. J. Hobel, A. Chicz-Demet, and C. A. Sandman, “Prenatal β-endorphin as an early predictor of postpartum depressive symptoms in euthymic women,” Journal of Affective Disorders, vol. 125, no. 1–3, pp. 128–133, 2010.
[127]
J. P. Burkett, L. L. Spiegel, K. Inoue, A. Z. Murphy, and L. J. Young, “Activation of-opioid receptors in the dorsal striatum is necessary for adult social attachment in monogamous prairie voles,” Neuropsychopharmacology, vol. 36, no. 11, pp. 2200–2210, 2011.
